B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37

Benzinga Newsdesk www.benzinga.com Positive 61.3%

Neg 0% Neu 0% Pos 61.3%

B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $37.